InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 332221

Wednesday, 11/06/2019 7:17:44 AM

Wednesday, November 06, 2019 7:17:44 AM

Post# of 345952
PS Targeting and all IP related data including the Bavituximab treated patients are being HIDDEN from public and all because some Merckly Big Pharmas want it for themselves it seems....and will the SEC FBI DOJ FDA etc etc do their jobs without being lobbied to not disrupt the Big Pharma Cartel ??

Face the facts ...the late Dr Thorpe likely murdered in his lab to have PS Targeting IP controlled going forward and has it been controlled ?

No...just look at prior posts and FBI involvement with monitoring work and personal emails from TOP medical institutions like MD Anderson to Memorial Sloan Kettering and dozens more which includes Indiana

Maybe instead of hiding advances in medicine...all related to PS Targeting IP and risk others jumping on the same IP yet they MAY call it that they are Targeting something else!

Did Min Yue work for US based Green Valley and learn things related to PS Targeting (which is why Omeros went public with the facts that there are two brakes and PS Targeting is required ....then Min Yue on the record to being with parent company China based Green Valley and now they filed for Alzheimer's approval first.

Let's face it ... PS Targeting ALWAYS had been the story ...yet John Springs Stafford tried to tell investors otherwise

A bonus this morning for those paying attention....remember the "Lockheed Martin" patent that would REQUIRE PS Targeting patents ...well PAV#1 on Min Yue Linkedin profile is Lockheed Martin. I said the same for PAV#1 being Brigitte Phan of Allergan immediately after the death of Dr Phil Thorpe and we all know Brigitte Phan was involver with a medical device patent with Peregrine Ramone Valencia and others

China approves Alzheimer's drug, inviting fresh debate in field with few successes

Nov 4, 2019

...
...

Reducing neuroinflammation is one of the proposed mechanisms of action for oligomannate, which Green Valley says reconditions dysbiosis of gut microbiota as well as reduces amyloid protein deposition.

Links between bacteria in the gut and Alzheimer's have been proposed before, and researchers from Green Valley made the case for oligomannate's beneficial role via this pathway in a September 2019 paper published in Cell Research.

"There is no question that this data further supports the emerging idea that modulation of the gut microbiome via treatments such as GV-971 or other strategies should be further explored as novel strategies to slow the progression of AD," wrote researchers from Washington University School of Medicine in St. Louis, in an accompanying piece. GV-971 is another name used by Green Valley for oligomannate.
..
..


https://www.biopharmadive.com/news/china-alzheimers-drug-oligomannate-approval-green-valley/566540/



Min Yue, DVM, MS, RAC

Director of Regulatory Affairs
- US Green Valley Pharmaceuticals, a Shanghai Green Valley Pharmaceuticals Company
Shanghai Green Valley Pharmaceutical CO.,LTD
University of Wisconsin-Madison
Indianapolis, Ind


About
Globally focused regulatory expert and leader with over 25 years of direct working experience and management positions at top pharmaceutical, medical device & diagnostics, CRO companies, and research institutes; Seasoned in project and people management with multi-cultural, multi-geographic and different level of communication skills; Frequently invited speaker for CIMDR, Q1 Productions, RAPS, FDA News, DIA, Indiana Life Sciences, and other industry associations since 2005. Direct China Q&RA team establishment and supervision experiences with full service of commercial quality, clinical and regulatory activities. Trained in Veterinary Medicine, Immunology and US Regulator Affairs Certified (RAC). I am now working with the great team at US Green Valley Pharmaceuticals to lead the regulatory strategies and planning for new drug development and commercialization globally.

Connections

See Min Yue,’s 2,395 connections
Discover who you know in common

See Min Yue,’s 2395 connections


An Alzheimer Disease (AD) new drug just...
An Alzheimer Disease (AD) new drug just...
Shared by Min Yue, DVM, MS, RAC
...
...


Experience

Shanghai Green Valley Pharmaceutical CO.,LTD
Director of Regulatory Affairs
Shanghai Green Valley Pharmaceutical CO.,LTD
Aug 2019 – Present
4 months

US
US Green Valley Pharmaceuticals, a Shanghai Green Valley Pharmaceutical Co. - Developing drugs that patients are yearning for, has led us to pave our way to innovation.
US Green Valley Pharmaceuticals, a Shanghai Green Valley Pharmaceutical Co. - Developing drugs that patients are yearning for, has led us to pave our way to innovation.
MinYue-Pharos Consulting - Focusing on US-China pharmaceutical, medical device and IVD businesses



Founder & President
MinYue-Pharos Consulting
- Focusing on US-China pharmaceutical, medical device and IVD businesses
Jan 2019 – Aug 2019
8 months

Indianapolis, Indiana Area

With my over 25 years working in pharmaceutical and medical device companies in the US, combining my background in veterinary medicine, immunology and biologic drug R&D, 15 years hand-on registration experiences in over 100 countries with focused 2-years management roles for China commercial quality and regulatory affairs, plus my vast professional network and committed partners located in the US, China and other countries, I am passionate in helping any aspects of medical product registrations and related processes. I can be reached by phone or email at 317-908-3013, m.yue@pharosmy.com.
With my over 25 years working in pharmaceutical and medical device companies in the US, combining my background in veterinary medicine, immunology and biologic drug R&D, 15 years hand-on registration experiences in over 100 countries with focused 2-years management roles for China commercial quality and regulatory affairs, plus my vast professional network and committed partners located in the US, China and other countries, I am passionate in helping any aspects of medical product...
Show more


Beckman Coulter
Sr. Manager of Global and China Regulatory Affairs & China Commercial Quality Management
Beckman Coulter
Oct 2013 – Dec 20185 years 3 months

Indianapolis, Indiana Area

Key Responsibilities:
• Global regulatory affairs for product registrations in rest of world countries including China clinical trials and submissions
• China commercial quality, and regulatory affairs (Q&RA) team establishment, staff hiring and development, and day to day operation management (Jan 2017 - Dec 2018)
• Medical device and IVD filing in the US, Canada
• Liaison between Beckman's manufacturing sites (located in the US, France, China, and India) and in-country affiliates/agents for product development strategies, planning, registrations and corporate communications.
Key Responsibilities:
• Global regulatory affairs for product registrations in rest of world countries including China clinical trials and submissions
• China commercial quality, and regulatory affairs (Q&RA) team establishment, staff hiring and development, and day to day operation management (Jan 2017 - Dec 2018)
• Medical device and IVD filing in the US, Canada
• Liaison between Beckman's manufacturing sites (located in the US, France, China, and India) and in-country...
..

PAREXEL
Sr. Regulatory Consultant - International
PAREXEL
Jan 2010 – May 20133 years 5 months

Bethesda, MD

Key Responsibilities:
• Project proposals, contracts writing and defending
• Project lead for client's project management
• Global regulatory strategies, planning and submissions
• Project budget, timeline and milestone management and problem solving
Key Responsibilities:
• Project proposals, contracts writing and defending
• Project lead for client's project management
• Global regulatory strategies, planning and submissions
• Project budget, timeline and milestone management and problem solving




Eli Lilly

Regulatory Manager/Consultant; Sr. Biochemist
Eli Lilly
Apr 1998 – Jan 201011 years 10 months

Indianapolis, IN

Key Responsibilities:
• International Regulatory Affairs (formerly IcRA) for Lilly's product registrations in rest of world (ROW) countries; agency correspondence and advisory meetings; cross-functional communications and regulatory guidance
• Affiliate staff training program management and short-term assignment staff supervision
• Sr. Biochemist in ADME drug disposition for large molecule drug development and GLP pre-clinical studies - writing protocols and study reports, develop drug development methods and conduct immunoassays
Key Responsibilities:
• International Regulatory Affairs (formerly IcRA) for Lilly's product registrations in rest of world (ROW) countries; agency correspondence and advisory meetings; cross-functional communications and regulatory guidance
• Affiliate staff training program management and short-term assignment staff supervision
• Sr. Biochemist in ADME drug disposition for large molecule drug development and GLP pre-clinical studies - writing protocols and study reports, develop...
Show more
Bayer
Research Scientist
Bayer
Aug 1996 – Apr 19981 year 9 months

Preclinical studies and GLP lab work.
Preclinical studies and GLP lab work.
University of Wisconsin-Madison

Research Associate
University of Wisconsin-Madison
Mar 1991 – Jul 19965 years 5 months

Monoclonal antibodies and allergy studies.
Monoclonal antibodies and allergy studies.
????????????

Chief Inspector
????????????
Mar 1986 – Mar 19915 years 1 month

Associate director in animal food product inspections and GMP audit.
Associate director in animal food product inspections and GMP audit.
Hunan Agricultural University

Assistant Professor
Hunan Agricultural University
Jan 1983 – Mar 19863 years 3 months

Teaching in Vet School - Veterinary Immunology.
Teaching in Vet School - Veterinary Immunology.



Education

University of Wisconsin-MadisonUniversity of Wisconsin-Madison
University of Wisconsin-Madison
M.S.Immunology
1993 – 1995

Hunan Agricultural UniversityHunan Agricultural University
Hunan Agricultural University
DVMVeterinary Medicine
1978 – 1982


Volunteer Experience

Indianapolis Chinese Performing Arts, Inc. (ICPAI)
Founder/President
Indianapolis Chinese Performing Arts, Inc. (ICPAI)
Jun 2004 – Present
15 years 6 months

Arts and Culture

A nonprofit organization to cultivate volunteers and leaders to promote culture, arts and diversity in central Indiana. The organization has 6 functional performing arts groups with over 200 active members ranged 3-65 years old. The major activities are routine practices and performances in dances, music, instruments, lions, drums, and Taiji with over 40 performing events each year. For more information, please visit www.icpai.org.
A nonprofit organization to cultivate volunteers and leaders to promote culture, arts and diversity in central Indiana. The organization has 6 functional performing arts groups with over 200 active members ranged 3-65 years old. The major activities are routine practices and performances in dances, music, instruments, lions, drums, and Taiji with over 40 performing events each year. For more information, please visit www.icpai.org.
Indianapolis Sister City Committee

Chair, Arts and Culture
Indianapolis Sister City Committee
Jan 2011 – Present
8 years 11 months


Arts and Culture

Licenses & Certifications
RAC
Regulatory Affairs Professionals Society (RAPS)
Issued Aug 2006
(See credentialExternal link)



Honors & Awards

Jefferson Award
Eli Lilly - United Way
Jan 2010

President Award
Eli Lilly
Mar 2000



Languages

English
Chinese
Japanese-Limited working proficiency



Organizations

Indianapolis Chinese Performing Arts, Inc. (ICPAI)
Founder/President
May 2004 – Present
Indianapolis Chinese Performing Arts (ICPAI) - ???????, is a not-for-profit organization established in 2004 with the following missions:
Organize and prepare Chinese traditional and cultural related shows, dances and performances. Perform and show at local cultural, celebration, and recreational related events. Promote Chinese traditional Tai Chi and other martial arts. Introduce cross culture performing arts and dances to Chinese community. Promote performing arts by organizing classes and activities for all age groups. Promote and support culture related activities such as exhibitions, shows and exchange programs. ICPAI has Functional Groups: ICPAI Show and Performance Group ???????; ICPAI Tai Chi Group ???????; ICPAI Little Flower Group ????????; ICPAI NewGen Group. Website: http://www.icpai.org. Contact: icpai2015@gmail.com
Indianapolis Chinese Performing Arts (ICPAI) - ???????, is a not-for-profit organization established in 2004 with the following missions:
Organize and prepare Chinese traditional and cultural related shows, dances and performances. Perform and show at local cultural, celebration, and recreational related events. Promote Chinese traditional Tai Chi and other martial arts. Introduce cross culture performing arts and dances to Chinese community. Promote performing arts by organizing classes and activities for all age groups. Promote and support culture related activities such as exhibitions, shows and exchange programs. ICPAI has Functional Groups: ICPAI Show and Performance Group ???????; ICPAI Tai Chi Group ???????; ICPAI Little Flower Group ????????; ICPAI NewGen Group. Website: http://www.icpai.org.
Contact: icpai2015@gmail.com

Websites

My company
http://www.beckmancoulter.comExternal link

My Hobby
http://www.indychineseperformingarts.orgExternal link

nutraMetrix consultant
http://www.nutrametrix.com/cynetExternal


People also viewed

Dinesha Ramie
System Engineer
Asc Manager at Lockheed Martin

Hsiao-Chi Lo
Manager, Regulatory Affairs at Regeneron Pharmaceuticals, Inc.

Hsiao-Ling Hung, PhD, RAC
Global Regulatory Strategy Lead, Lung Cancer Program

Xin Min Yue
Regulatory Consultant at Eli Lilly

Julie Gilmore, Ph.D
Chief Operating Officer at Eli Lilly and Company

Sue B.

Betty V. Wheatley
VOLUNTEER AND BOARD MEMBER at Hieronymus Mueller Muesum

Christine Drury
Associate Director, Research Communications at Indiana University School of Medicine

Tatiana Zadora
Principal, Studio Z, inc.

Valerie Brown
Analytics Consultant, Diabetes at Eli Lilly and Company
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News